CJC-1295 Evidence Base Graded by GRADE

What Is CJC-1295 and How Does It Differ from Other GHRH Analogues?

CJC-1295 is a synthetic 29-amino-acid peptide analogue of growth hormone-releasing hormone (GHRH 1-29). The version most studied in clinical literature contains a Drug Affinity Complex (DAC) technology that covalently binds the peptide to circulating albumin, extending its half-life from roughly 7 minutes (native GHRH 1-29) to approximately 6-8 days [1]. This is the variant used in Teichman et al. 2006. A second formulation, often labeled CJC-1295 without DAC or modified GRF 1-29, lacks the albumin-binding lysine modification and behaves pharmacokinetically more like sermorelin.

Understanding this distinction matters clinically. Many telehealth protocols and compounding pharmacies use the terms interchangeably, yet the pharmacokinetics differ by roughly 100-fold in half-life. A prescriber ordering "CJC-1295" without specifying DAC status may be prescribing an entirely different pharmacokinetic profile.

The DAC Mechanism

The DAC technology replaces lysine at position 27 with a maleimido-propionamide group. This group reacts with the free thiol on Cys-34 of circulating albumin, forming a covalent bond [1]. Because albumin has a half-life of approximately 19 days in healthy adults, the bound peptide is protected from dipeptidyl peptidase IV (DPP-IV) degradation and renal clearance. The result is a once-weekly or biweekly dosing interval rather than the multiple-daily injections required for sermorelin.

Comparison to Sermorelin

Sermorelin (GHRH 1-29 acetate) received FDA approval in 1997 for children with GH deficiency and was voluntarily withdrawn from the US market by Serono in 2008 for commercial reasons, not safety [2]. It remains the only FDA-approved GHRH fragment in modern US regulatory history. CJC-1295 has never received an Investigational New Drug (IND) application that progressed to a Phase 3 trial, and it has no New Drug Application (NDA) on record with the FDA.

Regulatory Position in 2025

The FDA classifies CJC-1295 as a bulk drug substance that may be used in 503A compounding only under specific conditions. The Outsourcing Facility (503B) pathway is not available for CJC-1295 as of the 2024 FDA bulk substances list update [3]. Prescribers should confirm that the dispensing pharmacy operates under a valid 503A license and that the compound meets USP <797> sterility standards.

The Teichman 2006 Trial: What the Data Actually Show

The single most-cited clinical study of CJC-1295 is Teichman SL et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006 [1]. This Phase 2, randomized, double-blind, placebo-controlled dose-escalation trial enrolled 65 healthy adults aged 21-61 years and remains the only peer-reviewed RCT of CJC-1295 with DAC in humans.

Study Design and Population

Participants were randomized to single SC doses of CJC-1295 DAC at 30, 60, 90, or 120 mcg/kg, or placebo. A multiple-dose cohort received two injections spaced 7-14 days apart. Exclusion criteria included obesity (BMI >30), diabetes, active pituitary disease, and prior GH therapy. The healthy, non-obese, non-diabetic population limits generalizability to the patients most likely to seek peptide therapy in a telehealth setting.

GH Secretion Results

Mean GH AUC increased 2- to 10-fold above baseline across dose groups, with the 60 and 90 mcg/kg cohorts showing the most consistent response [1]. The GH elevation followed a pulsatile pattern rather than a sustained plateau, consistent with preserved pituitary feedback. Peak GH levels occurred at 2-6 hours post-injection and then declined, though measurable elevation above baseline persisted for 6-8 days at higher doses.

IGF-1 Results

Serum IGF-1 rose 1.5- to 3-fold above baseline in active treatment groups, reaching statistical significance (P<0.001 vs. Placebo at 90 and 120 mcg/kg doses) [1]. IGF-1 elevation was sustained for up to 28 days after a single injection at the 120 mcg/kg dose. This duration of IGF-1 elevation has no parallel in any other peptide currently available through compounding channels.

Safety Profile in Teichman 2006

Adverse events were generally mild and transient. Injection-site reactions occurred in 43% of active-treatment participants vs. 7% placebo. Water retention was reported in 14% of treated subjects. Two participants experienced transient flushing within 30 minutes of injection, consistent with the known vasodilatory effect of GHRH peptides. No serious adverse events were reported. No clinically significant changes in fasting glucose, HbA1c, or cortisol were observed over the trial duration.

Applying GRADE Methodology to the CJC-1295 Evidence Base

GRADE (Grading of Recommendations, Assessment, Development and Evaluations) assesses evidence quality across five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias [4]. The starting point for an RCT evidence base is "High," and quality is downgraded based on identified limitations.

Domain 1: Risk of Bias

The Teichman 2006 trial was adequately randomized and double-blinded. However, it was sponsored by ConjuChem, the company that developed CJC-1295, and no independent replication has been published. Industry-sponsored single-trial evidence without replication earns a one-level downgrade in GRADE for risk of bias. Starting point: High. After downgrade: Moderate.

Domain 2: Inconsistency

There is no inconsistency to assess because there is only one human RCT. GRADE guidance specifies that a single trial cannot be evaluated for inconsistency across studies. The absence of replication is itself a limitation. Some clinicians interpret this as no downgrade; the more conservative reading treats sparse single-trial evidence as warranting a downgrade. Applied here: one-level downgrade. Running total: Low.

Domain 3: Indirectness

The trial population consisted of healthy adults with no diagnosed GH deficiency, GH-related disorder, or metabolic disease. The patients who receive CJC-1295 through compounding channels are typically adults with low-normal IGF-1, age-related GH decline, body composition goals, or recovery needs. None of these populations appear in the Teichman 2006 trial. This represents serious indirectness. One additional downgrade applies. Running total: Very Low.

Domain 4: Imprecision

N=65 is a small sample. The 95% confidence intervals around the IGF-1 and GH AUC estimates are wide. No minimum clinically important difference (MCID) was pre-specified for IGF-1 or GH AUC in the trial protocol. One downgrade for serious imprecision would be warranted, but GRADE allows stopping at Very Low even when additional domains are imprecise. The overall evidence grade for CJC-1295 GH/IGF-1 outcomes therefore holds at Very Low.

Domain 5: Publication Bias

No registry entry (ClinicalTrials.gov or equivalent) is available for the Teichman 2006 trial, which predates mandatory registration requirements. No Phase 3 trial, no long-term outcome data, and no head-to-head comparison against sermorelin or other GHRH analogues has been published. The probability of unpublished negative trials cannot be estimated. GRADE flags this as a concern without a formal additional downgrade given the Very Low floor already reached.

Summary GRADE Table

| Outcome | N (studies) | Downgrade reasons | GRADE quality | |---|---|---|---| | GH AUC elevation | 1 RCT (N=65) | Risk of bias, indirectness, imprecision | Very Low | | IGF-1 elevation | 1 RCT (N=65) | Risk of bias, indirectness, imprecision | Very Low | | Body composition | 0 RCTs | No human trial data | Not gradeable | | Safety/tolerability | 1 RCT (N=65) | Risk of bias, short follow-up, imprecision | Very Low | | Long-term CV outcomes | 0 RCTs | No data | Not gradeable |

What the Evidence Does Not Cover

Several outcomes that clinicians and patients ask about have zero controlled trial data in humans for CJC-1295.

Body Composition

No published RCT has assessed fat mass, lean mass, DEXA-measured body composition, or visceral adiposity as a primary or secondary endpoint for CJC-1295. The assumption that GH/IGF-1 elevation translates to body composition benefits is extrapolated from GH replacement trials in GH-deficient patients, a population with frankly subnormal GH secretion rather than the age-related decline typical of peptide therapy candidates [5].

Cognitive and Sleep Outcomes

Animal data and short-term polysomnography studies with GHRH infusion show increased slow-wave sleep [6]. No trial has assessed sleep architecture, cognitive performance, or subjective recovery using CJC-1295 specifically.

Long-Term Safety

The Teichman 2006 trial had a maximum observation window of 56 days. No data exist on cancer risk, glucose dysregulation, or pituitary desensitization beyond two months of CJC-1295 DAC exposure. The American Association of Clinical Endocrinology (AACE) 2023 guidelines on GH therapy note that exogenous GH and GH secretagogues share a theoretical concern for IGF-1-mediated mitogenesis, stating: "The long-term risk of GH secretagogue use in non-GH-deficient adults remains undefined and warrants caution in patients with a personal or family history of malignancy" [7].

Drug Interactions

No pharmacokinetic interaction studies have been published for CJC-1295 combined with insulin, GLP-1 receptor agonists (such as semaglutide or tirzepatide), thyroid hormone, or sex steroids. Given that the typical peptide therapy patient is frequently prescribed at least one of these agents, the absence of interaction data is a material clinical gap.

How HealthRX Interprets the GRADE Findings for Clinical Practice

A Very Low GRADE rating does not mean a therapy is unsafe or ineffective. It means the evidence is insufficient to make confident clinical recommendations. GRADE distinguishes between the quality of evidence and the strength of a recommendation. A weak recommendation for use in select patients could still be justified at Very Low evidence quality if the potential benefit is meaningful and the harm profile from available data is acceptable.

The HealthRX medical team interprets the CJC-1295 evidence as follows.

CJC-1295 DAC produces measurable, sustained GH and IGF-1 elevation in healthy adults. That is established by one small, industry-funded RCT. Whether this elevation produces clinically meaningful benefits in the population seeking peptide therapy (adults with age-related GH decline, body composition goals, or recovery purposes) is unknown. Whether long-term use poses meaningful risk beyond transient water retention and injection-site reactions is also unknown.

Prescribers operating under 503A compounding should document the rationale for use, confirm IGF-1 and fasting glucose at baseline, and re-check IGF-1 at 8-12 weeks to verify a response and avoid supraphysiologic levels. The Endocrine Society's position on GH secretagogues states that use outside of approved GH deficiency indications "should occur only in the context of clinical research or well-monitored individualized care with full informed consent regarding the limited evidence base" [8].

IGF-1 targets should remain within age- and sex-adjusted reference ranges. An IGF-1 above the 97.5th percentile for age should prompt dose reduction or discontinuation regardless of patient-reported outcomes.

Dosing Protocols Referenced in the Literature

The Teichman 2006 trial used weight-based dosing (30-120 mcg/kg SC) for research purposes [1]. Compounding protocols in clinical practice have standardized on fixed doses for practical reasons.

CJC-1295 With DAC

The most commonly compounded dose is 1-2 mg SC once weekly or every two weeks. This approximates the 60-90 mcg/kg range used in Teichman 2006 for a 70-80 kg adult. Some protocols extend to biweekly dosing given the prolonged IGF-1 elevation observed at 8+ days in the trial. Cycling (e.g., 12 weeks on, 4 weeks off) is commonly recommended in prescribing guidelines, though no trial data support a specific cycle length.

CJC-1295 Without DAC (Modified GRF 1-29)

Without the albumin-binding modification, the half-life drops to roughly 30 minutes. This formulation is typically dosed at 100-200 mcg SC daily, often combined with a ghrelin mimetic such as ipamorelin (100-200 mcg SC) to produce a synergistic GH pulse [9]. No RCT has studied the combination in humans.

Monitoring Parameters

• Baseline: IGF-1 (age/sex-adjusted), fasting glucose, HbA1c, CBC, CMP
• 8-12 weeks: IGF-1 repeat, fasting glucose
• Ongoing: IGF-1 every 6 months; annual fasting glucose if baseline was normal
• Discontinue if IGF-1 exceeds 97.5th percentile for age or fasting glucose rises >100 mg/dL from a normal baseline

Ongoing Research and Evidence Gaps

As of January 2025, no new human RCTs of CJC-1295 have been registered on ClinicalTrials.gov since the Teichman 2006 publication [10]. This near-20-year absence of follow-up trials is unusual for a compound with this degree of clinical prescribing activity. The research gap is likely explained by the compound's status as an unpatentable, off-patent peptide: no commercial sponsor has a financial incentive to fund Phase 3 trials.

Animal studies have examined CJC-1295 effects on muscle hypertrophy in rodent models, with one 2010 study showing increased tibialis anterior mass after 4 weeks of dosing, but rodent GH physiology differs substantially from human pulsatile GH secretion patterns [11].

The endocrinology research community would benefit substantially from an investigator-initiated trial examining CJC-1295 versus placebo in adults aged 40-65 with confirmed low-normal IGF-1 (<100 ng/mL), using DEXA body composition, insulin sensitivity (HOMA-IR), and quality-of-life measures as co-primary endpoints. Such a trial would take the evidence base from Very Low to at least Moderate under GRADE, assuming adequate sample size and independent funding.